Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [15436]

SABCS 2018: Adjuvant chemotherapy might not add benefit in breast cancer patients who have excellent response to neoadjuvant chemotherapy

SABCS 2018: Adjuvant chemotherapy might not add benefit in breast cancer patients who have excellent response to...

SABCS 2018: Adjuvant capecitabine did not significantly improve outcomes for patients with early-stage triple-negative breast cancer

SABCS 2018: Adjuvant capecitabine did not significantly improve outcomes for patients with early-stage triple...

ASH 2018: Cancer patients show reduced risk of harmful clots while taking direct oral anticoagulants

ASH 2018: Cancer patients show reduced risk of harmful clots while taking direct oral anticoagulants

ASH 2018: Ibrutinib-based therapy more effective, safer in younger patients with previously untreated CLL compared with current standard of care

ASH 2018: Ibrutinib-based therapy more effective, safer in younger patients with previously untreated CLL compared...

ASH 2018: Researchers identify mutation in BCL2 protein that causes resistance to venetoclax

ASH 2018: Researchers identify mutation in BCL2 protein that causes resistance to venetoclax

ASH 2018: Daratumumab increases progression-free survival in transplant-ineligible multiple myeloma

ASH 2018: Daratumumab increases progression-free survival in transplant-ineligible multiple myeloma

ASH 2018: Rapid genetic screening shows feasibility of precision medicine for acute myeloid leukaemia

ASH 2018: Rapid genetic screening shows feasibility of precision medicine for acute myeloid leukaemia

ASH 2018: Disruptions in the gut microbiota before hematopoietic cell transplantation associated with worse outcomes

ASH 2018: Disruptions in the gut microbiota before hematopoietic cell transplantation associated with worse...

ASH 2018: A first stem cell transplant after CAR T-Cell therapy reduces relapses in ALL

ASH 2018: A first stem cell transplant after CAR T-Cell therapy reduces relapses in ALL

ASH 2018: Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy

ASH 2018: Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy

More from ecancer